<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155999</url>
  </required_header>
  <id_info>
    <org_study_id>LT1225-PIIIB-02/08</org_study_id>
    <secondary_id>2008-003567-39</secondary_id>
    <nct_id>NCT01155999</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Tunisia: Ministry of Public Health</authority>
    <authority>Algeria: Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent
      bacterial conjunctivitis of children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical cure was defined as a score 0 for bulbar conjunctival injection (evaluated using a 4 point ordinal scale) and a score 0 for conjunctival purulent discharge (evaluated using a 4 point ordinal scale).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">286</enrollment>
  <condition>Purulent Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>T1225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T1225</intervention_name>
    <description>one drop twice daily (morning and evening) in each eye from Day 0 to Day 2</description>
    <arm_group_label>T1225</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin</intervention_name>
    <description>1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6</description>
    <arm_group_label>Tobramycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ one day of life and ≤ 18 years

          -  Purulent bacterial conjunctivitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>October 24, 2014</lastchanged_date>
  <firstreceived_date>June 30, 2010</firstreceived_date>
  <firstreceived_results_date>October 24, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T1225</title>
          <description>T1225: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2</description>
        </group>
        <group group_id="P2">
          <title>Tobramycin</title>
          <description>Tobramycin: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T1225</title>
          <description>T1225: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2</description>
        </group>
        <group group_id="B2">
          <title>Tobramycin</title>
          <description>Tobramycin: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="146"/>
                <measurement group_id="B2" value="136"/>
                <measurement group_id="B3" value="282"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.06" spread="3.40"/>
                <measurement group_id="B2" value="3.52" spread="4.17"/>
                <measurement group_id="B3" value="3.28" spread="3.79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="76"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="144"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="70"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="138"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Portugal</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Romania</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Algeria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Tunisia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3</title>
        <description>Clinical cure was defined as a score 0 for bulbar conjunctival injection (evaluated using a 4 point ordinal scale) and a score 0 for conjunctival purulent discharge (evaluated using a 4 point ordinal scale).</description>
        <time_frame>Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis of the primary clinical efficacy variable was primarily performed on the basis of the MFAS. The MFAS consisted of all patients of the FAS with positive Day 0 culture results in an eligible eye.</population>
        <group_list>
          <group group_id="O1">
            <title>T1225</title>
            <description>T1225: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin</title>
            <description>Tobramycin: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3</title>
            <description>Clinical cure was defined as a score 0 for bulbar conjunctival injection (evaluated using a 4 point ordinal scale) and a score 0 for conjunctival purulent discharge (evaluated using a 4 point ordinal scale).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>T1225</title>
          <description>T1225: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2</description>
        </group>
        <group group_id="E2">
          <title>Tobramycin</title>
          <description>Tobramycin: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pascale Pouliquen (Medical director)</name_or_title>
      <organization>Laboratoires Thea</organization>
      <phone>0473963614</phone>
      <email>p.pouliquen@laboratoires-thea.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
